Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Market Closed - Toronto S.E.
Other stock markets
 03:46:55 2024-06-06 pm EDT 		5-day change 1st Jan Change
3.65 CAD 0.00% Intraday chart for Eupraxia Pharmaceuticals Inc. -4.20% -32.03%
Jun. 05 Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 MT
May. 23 Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
AQ
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
AQ
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
AQ
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
AQ
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
AQ
Eupraxia Pharmaceuticals : Name and Address of Company - Form 6-K
PU
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
PR
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
PR
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
PR
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
AQ
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
AQ
Eupraxia Pharmaceuticals : Name and Address of Company - Form 6-K
PU
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million
GL
Canadian Investment Regulatory Organization Trade Resumption - EPRX
AQ
Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million
GL
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million
GL
Canadian Investment Regulatory Organization Trading Halt - EPRX
AQ
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
AQ
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. News Eupraxia Pharmaceuticals Inc.
  5. Press Releases